Upstream Bioprocessing 2021

Vectors

Upstream Bioprocessing 2021

Upstream Bioprocessing 2021
Scalable cell culture and transient transfection for viral vector manufacturing

Scalable cell culture and transient transfection for viral vector manufacturing

Ann Rossi Bilodeau
20 September 2021
FastFacts
Scale up of a lentiviral production process from the iCELLis<sup>®️</sup> Nano Bioreactor to the iCELLis 500+ Bioreactor

Scale up of a lentiviral production process from the iCELLis®️ Nano Bioreactor to the iCELLis 500+ Bioreactor

Isabelle Pelletier, Kaitlynn Bayne
22 September 2021
FastFacts
Evaluation of a microbioreactor system as a screening tool for optimizing lentiviral vector process development in suspension culture

Evaluation of a microbioreactor system as a screening tool for optimizing lentiviral vector process development in suspension culture

N Sutherland, L Chan, K Kral et al.
22 September 2021
Innovator Insight
Enabling development of commercial-ready lentiviral vector manufacturing processes using stable producer cell lines

Enabling development of commercial-ready lentiviral vector manufacturing processes using stable producer cell lines

Peter Archibald, Ph.D, Anthony Shillings
22 September 2021
Commentary
Scalability comparison between 50 and 500 liter stirred tank bioreactor for production of rAAV viral vector

Scalability comparison between 50 and 500 liter stirred tank bioreactor for production of rAAV viral vector

T P Sanderson, T Erlandson, N Hazi et al.
23 September 2021
Innovator Insight
Overview of major AAV production platforms

Overview of major AAV production platforms

Jote Bulcha
24 September 2021
Viewpoint
Utilizing a media panel rapidly accelerates media optimization for AAV manufacturers

Utilizing a media panel rapidly accelerates media optimization for AAV manufacturers

Céline Martin, Jennifer Zatina
28 September 2021
Innovator Insight
Addressing HEK293 cell lineage and AAV diversity with media panel

Addressing HEK293 cell lineage and AAV diversity with media panel

Jennifer A Schieber
29 September 2021
FastFacts
Achieving cost-effective, scalable high-titer AAV production

Achieving cost-effective, scalable high-titer AAV production

Chao Yan Liu
30 September 2021
FastFacts
Leveraging lessons from the COVID-19 pandemic to accelerate the development and production of viral-based gene therapies

Leveraging lessons from the COVID-19 pandemic to accelerate the development and production of viral-based gene therapies

Yasser Kehail
5 October 2021
FastFacts
Key considerations for maximizing LV and AAV production in transient transfection workflows

Key considerations for maximizing LV and AAV production in transient transfection workflows

Beth Larimore
8 October 2021
Innovator Insight
Development of a scalable AAV production process in suspension cells

Development of a scalable AAV production process in suspension cells

Ann-Christin Magnusson
11 November 2021
FastFacts
Transfer and scale-up from 10 L BioBLU<sup>®️</sup> to Allegro™ STR 50 and STR 200 Bioreactors

Transfer and scale-up from 10 L BioBLU®️ to Allegro™ STR 50 and STR 200 Bioreactors

D Mainwaring, A Joshi, J Coronel et al.
25 November 2021
Innovator Insight

Other editions


<< Back to Vectors channel